Organigram Analyst Cuts Price Target, Lowers Sales Estimates Ahead Of Q1 Report

Organigram Holdings Inc. OGI shares lost 63.58% over the past 12 months. Cantor Fitzgerald lowered its price target Monday for the cannabis company ahead of its first-quarter report on Jan. 27.

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

• Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
• Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
• Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.

Share Price: $0.80

Min. Investment: $1,000

Valuation: $3.5B

Click Here To Invest For Just $0.80/Share ($1000 Min)

The Organigram Analyst

Pablo Zuanic maintained an Overweight rating on Organigram and cut the price target from CA$13.30 ($10.25) to CA$9.50 ($7.32).

The Organigram Thesis

In order to mirror market share that's more in line with the August quarter than prior quarters, Cantor trimmed its sales estimates for Organigram, Zuanic said in a Monday note. (See his track record here.) 

The January and May quarters were not a true representation of the underlying movements considering the effects of price discounts and returns, the analyst said. 

The consensus estimates are high, Zuanic said, adding that Cantor is 5% below the Street on sales — and 40% below the conensus adjusted gross margin estimate. 

"That said, OGI remains one of the most cost-efficient operators in Canada, with a focused approach, and we continue to think the valuation is attractive (3x 1yF EV/Sales compared with most direct peers at 7-8x)." 

It will take a while for Organigram to regain credibility after the company's August quarter, the analyst said. 

Organigram experienced a significant drop to $16 million in net sales in the August quarter versus net sales of $25-27 million in the second and third quarters, he said, adding that “we expect minor improvements to $18Mn in the Nov Qtr.”

Organigram Price Action

Organigram shares were down 3.52% at $2.19 at the time of publication. 

Related Links:

Aurora Cannabis Analyst Lowers Price Target, Says Company Needs 'Greater Financial Discipline'

Organigram Receives Health Canada Licenses For Chocolate Production